Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

Nishimoto, Norihiro; Miyasaka, Nobuyuki; Yamamoto, Kazuhiko; Kawai, Shinichi; Takeuchi, Tsutomu; Azuma, Junichi; Kishimoto, Tadamitsu

doi:10.1007/s10165-008-0125-1

Public

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

Published in Modern Rheumatology • Oct 31, 2008

Authors:

Norihiro Nishimoto

Nobuyuki Miyasaka

Kazuhiko Yamamoto

Abstract

We investigated the clinical efficacy and safety of tocilizumab (a humanized anti-IL-6 receptor antibody) monotherapy in active rheumatoid arthritis (RA) patients with an inadequate response to low dose methotrexate (MTX). In a multicenter, double-blind, randomized, controlled trial, 125 patients we...

Subject

Tocilizumab

Medicine

Rheumatoid arthritis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!